| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Clinical decision‐making and treatment of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
Oncologist |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| A Journey from Blood Cells to Genes and Back |
|
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
